ST 266

Drug Profile

ST 266

Alternative Names: ST-266

Latest Information Update: 07 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Noveome
  • Developer Noveome; University of Pennsylvania
  • Class Anti-inflammatories; Growth factors; Intercellular signalling peptides and proteins; Neuroprotectants; Proteins; Small molecules
  • Mechanism of Action Paracrine communication modulators; Proto oncogene protein c akt modulators; SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic conjunctivitis; Periodontitis
  • Phase I Burns; Dry eyes; Gingivitis
  • Preclinical Optic neuritis; Unspecified

Most Recent Events

  • 31 Jan 2017 Preclinical trials in Optic neuritis in USA (Intranasal) before January 2017
  • 31 Jan 2017 Pharmacodynamics data from a preclinical trial in Optic neuritis released by Noveome Biotherapeutics
  • 05 Dec 2016 Phase-II clinical trials in Allergic conjunctivitis in USA (Ophthalmic) (NCT02978183)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top